A 52-year-old man with major depressive disorder and chronic neuropathic pain from diabetic peripheral neuropathy presents for antidepressant initiation. He has no cardiac contraindications. Which antidepressant is most appropriate as first-line therapy given his comorbid pain condition?

Explanation

## Antidepressant Selection in Depression with Comorbid Chronic Pain **Key Point:** When major depressive disorder coexists with chronic pain syndromes (neuropathic pain, fibromyalgia, chronic musculoskeletal pain), serotonin–norepinephrine reuptake inhibitors (SNRIs) are preferred over SSRIs because they target both monoamine systems implicated in pain modulation. ### SNRIs: Mechanism and Pain Efficacy **Mnemonic:** **SNRIs = Dual action** — both serotonin AND norepinephrine reuptake inhibition. | SNRI | Dose (mg/day) | Serotonin Inhibition | Norepinephrine Inhibition | Pain Indication | |------|---------------|----------------------|---------------------------|------------------| | Venlafaxine | 75–225 | ✓ Strong | ✓ Strong (dose-dependent) | Neuropathic pain, fibromyalgia | | Duloxetine | 60–120 | ✓ Strong | ✓ Strong | Neuropathic pain, fibromyalgia, chronic pain | | Desvenlafaxine | 50–100 | ✓ Strong | ✓ Strong | Neuropathic pain | **High-Yield:** Venlafaxine and duloxetine have the strongest evidence base for efficacy in neuropathic pain and are FDA/WHO-approved for this indication. ### Clinical Pearl **Tip:** In this patient—depression + diabetic neuropathic pain—venlafaxine is an excellent choice because: 1. It treats both the mood disorder and the pain syndrome with a single agent. 2. Norepinephrine reuptake inhibition (especially at doses ≥150 mg/day) enhances descending pain inhibitory pathways. 3. It reduces the need for polypharmacy and improves adherence. ### Why Other Options Are Suboptimal - **Fluoxetine (SSRI)**: Effective for depression but minimal efficacy for neuropathic pain. Lacks norepinergic activity needed for pain modulation. Would require concurrent pain medication (e.g., gabapentin, pregabalin, tricyclic). - **Bupropion (NDRI)**: Unique mechanism (norepinephrine–dopamine reuptake inhibition); activating but poor efficacy for pain syndromes. Contraindicated in seizure disorders; not indicated for neuropathic pain. - **Mirtazapine (Tetracyclic)**: Sedating; useful in depression with insomnia but minimal evidence for neuropathic pain efficacy. Alpha-2 antagonism may worsen some pain conditions. ## Evidence Summary SNRIs (venlafaxine, duloxetine) have Level A evidence for efficacy in: - Diabetic peripheral neuropathic pain - Fibromyalgia - Chronic musculoskeletal pain - Postherpetic neuralgia [cite:Harrison 21e Ch 470; Uptodate Neuropathic Pain Management]